Vergoeding 2019-2023 voor ATC-subgroep L04AC : Interleukineremmers
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021* | 2022* | 2023* | |
|---|---|---|---|---|---|
| L04AC03 Anakinra | 3.446.944 | 4.012.922 | 4.023.770 | 4.328.572 | 4.369.405 |
| L04AC05 Ustekinumab | 61.661.560 | 72.573.609 | 88.797.715 | 104.807.767 | 131.532.006 |
| L04AC07 Tocilizumab | 28.370.910 | 28.445.914 | 37.700.815 | 30.813.016 | 34.923.803 |
| L04AC08 Canakinumab | 18.096.527 | 22.698.685 | 26.598.065 | 28.812.921 | 30.158.368 |
| L04AC10 Secukinumab | 23.290.372 | 24.456.853 | 29.600.525 | 31.262.229 | 33.381.310 |
| L04AC11 Siltuximab | 66.054 | 42.935 | 71.986 | 98.112 | 103.658 |
| L04AC12 Brodalumab | 803.222 | 949.513 | 2.849.732 | 2.480.600 | 2.223.603 |
| L04AC13 Ixekizumab | 7.523.600 | 9.248.031 | 10.318.522 | 12.105.299 | 15.088.840 |
| L04AC14 Sarilumab | 1.619.684 | 2.555.961 | 5.109.864 | 3.664.202 | 3.207.854 |
| L04AC16 Guselkumab | 5.871.835 | 7.967.544 | 10.252.580 | 12.821.411 | 15.610.098 |
| L04AC17 Tildrakizumab | . | 657.342 | 1.886.673 | 1.680.063 | 1.219.461 |
| L04AC18 Risankizumab | 326.835 | 2.065.251 | 4.741.838 | 7.252.786 | 9.210.588 |
| L04AC21 Bimekizumab | . | . | 63.239 | 948.160 | 1.771.990 |
| Totaal | 151.077.543 | 175.674.561 | 222.015.325 | 241.075.139 | 282.800.984 |